NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia THOUSAND OAKS, Calif., Nov. 12, 2024 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced new preclinical data for CAP-004, a potential best-in-class…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.